A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05732831

Title field or adapter rule

{'original_value': 'A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:26.423698+00:00

Published At

2026-09-08T00:00:00+00:00

Record Updated At

2026-09-08

Source Retrieved At

2026-10-31T22:17:58.991924+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Locally Advanced Solid Tumor"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-08", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT05732831"

protocolSection.identificationModule.officialTitle

"A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Locally Advanced Solid Tumor (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Dose Escalation', 'Dose Expansion in Mesothelioma', 'Dose Expansion in NSCLC', 'Dose Expansion in NSCLC in Combination with Pembrolizumab', 'Dose Expansion in Pancreatic Ductal Adenocarcinoma', 'Dose Expansion in Sarcoma', 'Dose Expansion in Solid Tumors'], 'description': 'TNG462, a selective PRMT5 inhibitor, will be administered orally', 'name': 'TNG462', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Dose Escalation', 'Dose Expansion in NSCLC in Combination with Pembrolizumab'], 'description': 'An anti PD-1 antibody, will be administered intravenously', 'name': 'Pembrolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• TNG462 (protocolSection.armsInterventionsModule.interventions[].name)
• Pembrolizumab (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.